Demystifying Mineralocorticoid Receptor Antagonists in HFpEF: From Spironolactone to Finerenone

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/cd/59/5b/cd595bbc-f9c1-7061-9683-bc8f601c435f/mza_16890736107849223793.jpg/600x600bb.jpg

Heart Failure to Success

HFAI

4 episodes

1 week ago

Heart Failure to Success” is a doctor-to-doctor podcast series bringing together leading cardiologists and healthcare experts. Each episode explores the latest advances, real-world challenges, and clinical strategies in heart failure management—sharing knowledge that helps transform practice into success. It’s a platform to exchange expertise, sharpen perspectives, and drive better clinical outcomes.

Health & Fitness

RSS

All content for Heart Failure to Success is the property of HFAI and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/44320343/44320343-1756376077313-8c4ec9c0b0873.jpg

Demystifying Mineralocorticoid Receptor Antagonists in HFpEF: From Spironolactone to Finerenone

Heart Failure to Success

21 minutes 6 seconds

1 month ago

Demystifying Mineralocorticoid Receptor Antagonists in HFpEF: From Spironolactone to Finerenone

Demystifying the use of Mineralocorticoid Receptor Antagonists(MRAs) in HFpEF.

Spironolactone and the TOPCAT trial in HFpEF are reported negative but trial is mired with some controversies that is discussed. Future trials previewed.

Steroidal and nonsteroidal MRAs simplified.

Finerenone is the new MRA - the FINE ART trial and the FINEHEART meta - analysis efficacy and safety are outlined.

Finally an approach to the management of HFpEF in clinical practice.